Journal Scans
Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methyl-Guanine-DNA Methyltransferase as a Potential Biomarker
Temozolomide in Relapsed or Refractory Small-Cell Lung Cancer
MC Pietanza, K Kadota, K Huberman, CS Sima, LM Krug, et al
20120006
2012 Jan 6
Clin Cancer Res
Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methyl-Guanine-DNA Methyltransferase as a Potential Biomarker
Clin Cancer Res. 2012 Jan 6;[Epub Ahead of Print], MC Pietanza, K Kadota, K Huberman, CS Sima, LM Krug, et al
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Small-cell lung cancer (SCLC) is a disease with a high rate of initial chemo-responsiveness, but a challenging tendency to recur. There are, at present, a limited number of effective next-line therapies when SCLC recurs or proves refractory to platinum-based chemotherapy. Monotherapy with alkylating agents can be effective in this setting, and temozolomide is an oral alkylator that has most famously shown promise in the treatment of glioblastoma multiforme (GBM), where MGMT promoter methylation has...
